M
Maurice Markus
Researcher at University of Colorado Colorado Springs
Publications - 5
Citations - 2388
Maurice Markus is an academic researcher from University of Colorado Colorado Springs. The author has contributed to research in topics: Pembrolizumab & Axitinib. The author has an hindex of 3, co-authored 5 publications receiving 1250 citations. Previous affiliations of Maurice Markus include Merck & Co..
Papers
More filters
Journal ArticleDOI
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Boris Alekseev,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Anna Kryzhanivska,Igor Bondarenko,Sergio J Azevedo,Delphine Borchiellini,Cezary Szczylik,Maurice Markus,Raymond S. McDermott,Jens Bedke,Sophie Tartas,Yen-Hwa Chang,Satoshi Tamada,Qiong Shou,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles +26 more
TL;DR: Treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression‐free survival, as well as a higher objective response rate, than treatment with sunitin ib among patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Thomas Powles,Thomas Powles,Tibor Csőszi,Mustafa Ozguroglu,Nobuaki Matsubara,Lajos Géczi,Susanna Y-S Cheng,Yves Fradet,Stéphane Oudard,Christof Vulsteke,Rafael Morales Barrera,Aude Flechon,Seyda Gunduz,Yohann Loriot,Alejo Rodriguez-Vida,Ronac Mamtani,Evan Y. Yu,Evan Y. Yu,Kijoeng Nam,Kentaro Imai,Blanca Homet Moreno,Ajjai Alva,Diana Vera Cascallar,Mirta Varela,Mauricio Fernandez Lazzaro,Diego Lucas Kaen,Gabriela Gatica,David Hugo Flores,Agustin Falco,Matias Molina,Filip Van Aelst,Brieuc Sautois,Jean-Pascal Machiels,Denis Schallier,Leandro Brust,Liane Rapatoni,Sergio J Azevedo,Gisele Marinho,Joao Paulo Holanda Soares,Carlos Dzik,Jamile Almeida Silva,Andre P. Fay,Joel Gingerich,Cristiano Ferrario,Kylea Potvin,Marie Vanhuyse,Mahmoud Abdelsalam,Susanna Cheng,Christian Caglevic,Felipe Reyes,Jose Luis Leal,Francisco Francisco,Carolina Ibanez,Florence Joly,Brigitte Laguerre,Sylvain Ladoire,Delphine Topart,Olivier Huillard,Marine Gross-Goupil,Stéphane Culine,Gwenaelle Gravis,Peter Reichardt,Margitta Retz,Jan Herden,David G. Pfister,Carsten Ohlman,Michael Stoeckle,Manfred P. Wirth,Anja Lorch,Guenter Niegisch,Peter J. Goebell,Martin Boegemann,Axel S. Merseburger,Georgios Gakis,Jens Bedke,Andreas Neisius,Christian Thomas,Thomas Hoefner,Andras Telekes,Judit Erzsebet Kosa,János Révész,György Bodoky,Tibor Csoszi,Andras Csejtei,Agnes Ruzsa,Zsuzsanna Kolonics,Jozsef Erfan,Ray McDermott,Richard Bambury,Avishay Sella,Stephen Jay Frank,Daniel Kejzman,Olesya Goldman,Eli Rosenbaum,Avivit Peer,Raanan Berger,Keren Rouvinov,David Sarid,Satoshi Fukasawa,Gaku Arai,Akito Yamaguchi,Akira Yokomizo,Tatsuya Takayama,Hidefumi Kinoshita,Eiji Kikuchi,Ryuichi Mizuno,Yasuhisa Fujii,Naoto Sassa,Yoshihisa Matsukawa,Kiyohide Fujimoto,Toshiki Tanikawa,Yoshihiko Tomita,Kazuo Nishimura,Masao Tsujihata,Masafumi Oyama,Naoya Masumori,Hiroomi Kanayama,Toshimi Takano,Yuji Miura,Jun Miyazaki,Akira Joraku,Tomokazu Kimura,Yoshiaki Yamamoto,Kazuki Kobayashi,Ronald de Wit,Maureen J.B. Aarts,Winald R. Gerritsen,Maartje Los,Laurens V. Beerepoot,Adel Izmailov,Sergey Igorevich Gorelov,Boris Alekseev,Andrey Semenov,Vladimir Anatolyevich Kostorov,Sergey M Alekseev,Alexander Zyryanov,Vasiliy Nikolaevich Oschepkov,Vladimir Aleksandrovich Shidin,Vladimir Ivanovich Vladimirov,Rustem Gafanov,Petr Alexandrovich Karlov,David Brian Anderson,Lucinda Shepherd,Graham Lawrence Cohen,Bernardo Louis Rapoport,Paul Ruff,Nari Lee,Woo Kyun Bae,Hyo Jin Lee,Urbano Anido Herranz,Enrique Grande,Teresa Alonso Gordoa,Josep Guma Padro,Daniel Castellano Gauna,Jose Angel Arranz,Jose Munoz Langa,Regina Gironés Sarrió,Alvaro Montesa Pino,Maria Jose Juan Fita,Yu-Li Su,Yung-Chang Lin,Wen-Pin Su,Ying-Chun Shen,Yen-Hwa Chang,Yi-Hsiu Huang,Virote Sriuranpong,Phichai Chansriwong,Vichien Srimuninnimit,Pongwut Danchaivijitr,Huseyin Abali,Sinan Yavuz,Ozgur Ozyilkan,Mehmet Ali Nahit Sendur,Meltem Ekenel,Cagatay Arslan,Mustafa Ozdogan,Alison Birtle,Robert Huddart,Maria De Santis,Anjali Zarkar,Linda Evans,Syed A. Hussain,Christopher DiSimone,Antonio F Muina,Peter Schlegel,Haresh S Jhangiani,Michael R. Harrison,Dennis E Slater,David Wright,Ivor J. Percent,Jianqing Lin,Clara Hwang,Sumati Gupta,Madhuri Bajaj,Robert Galamaga,John Eklund,James Wallace,Mikhail Shtivelband,Jason Jung-Gon Suh,Nafisa Burhani,Matthew Eadens,Krishna Gunturu,Earle Burgess,John Wong,Arvind Chaudhry,Peter J. Van Veldhuizen,Stephanie Graff,Christian A Thomas,Ian D. Schnadig,Benedito A. Carneiro,Maha Hussain,Alicia K. Morgans,John T Fitzharris,Ira A Oliff,Jacqueline Vuky,Ralph Hauke,Ari David Baron,Monika Joshi,Britt H Bolemon,Peter Jiang,Anthony Mega,Maurice Markus,Nicklas Pfanzelter,William E. Lawler,Patrick Wayne Cobb,Jay Courtright,Sharad Jain,Gurjyot Doshi,Vijay K Gunuganti,Oliver Sartor,Scott W Cole,Hani M. Babiker,Edward Uchio,Alexandra Drakaki,Heather D Mannuel,Elizabeth A. Guancial,Chunkit Fung,Anthony Charles,Robert J Amato,Yull Arriaga,Isaac Bowman,Steven Ades,Robert Dreicer,Evan Yu,David I. Quinn,Mark D. Fleming +245 more
TL;DR: In this paper, the authors assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.
Journal ArticleDOI
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.
Thomas Powles,Juergen E. Gschwend,Yohann Loriot,Joaquim Bellmunt,Lajos Géczi,Christof Vulsteke,Mahmoud Abdelsalam,Rustem Gafanov,Woo Kyun Bae,János Révész,Yoshiaki Yamamoto,Urbano Anido,Wen-Pin Su,Mark D. Fleming,Maurice Markus,Dai Feng,Christian Heinrich Poehlein,Ajjai Alva +17 more
TL;DR: A small number of patients with advanced bladder cancer attain long-term survival with standard first-line cisplatin-based chemotherapy with programmed death 1 (PD-1)/PD-L1 inhibiting chemotherapy, and this data indicates that a second line therapy is needed.
Journal ArticleDOI
Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.
Elizabeth R. Plimack,Thomas Powles,Jens Bedke,Frédéric Pouliot,Viktor Stus,Thomas K. Waddell,Rustem Gafanov,Dmitry Nosov,Boris Alekseev,Raymond S. McDermott,Maurice Markus,Sophie Tartas,Anna Kryzhanivska,Igor Bondarenko,Cezary Szczylik,Jianxin Lin,Rodolfo F. Perini,L Rhoda Molife,Michael B. Atkins,Brian I. Rini +19 more
TL;DR: Pembrolizumab + axitinib significantly improved overall survival (OS), progression-free survival (PFS), and overall mortality in the randomized, open-label, phase III KEYNOTE-426 study as mentioned in this paper.
Journal ArticleDOI
Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial
Thomas Powles,Jürgen E. Gschwend,Yohann Loriot,Joaquim Bellmunt,Lajos Géczi,Christof Vulsteke,Mahmoud Abdelsalam,Rustem Gafanov,Woo Kyun Bae,János Révész,Yoshiaki Yamamoto,Urbano Anido,W. Su,Mark D. Fleming,Maurice Markus,D. Feng,Christian Heinrich Poehlein,Ajjai Alva +17 more